X

Assessing the Efficacy of Cholecalciferol Versus Ergocalciferol for Vitamin D Repletion in Chronic Kidney Disease

By: Nancy Yousry, PharmD Candidate c/o 2024               Vitamin D is a multifaceted nutrient needed to maintain homeostasis and proper…

eMAR

6th Year Perspective: APPE Rotations at the Westchester Medical Center Bundle

Featuring: Justin Budz, PharmD Candidate c/o 2023By: Isabelle Lim, PharmD Candidate c/o 2024 Justin Budz is a sixth-year pharmacy student…

eMAR

Evaluating Treatments and Preventative Measuresfor Monkeypox

By: Sairah Sheikh, PharmD Candidate c/o 2024 ​              As Coronavirus Disease 2019 (COVID-19) cases started to decrease in the United…

eMAR

FDA Approval of Pemazyre® as a First-in-Class Treatment forMyeloid / Lymphoid Neoplasms with FGFR1 Rearrangement

By: Jennifer Galvet, PharmD Candidate c/o 2024               Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases…

eMAR

Relyvrio: A New FDA-Approved Medication for Amyotrophic Lateral Sclerosis

By: Yu Jeng Lee, PharmD Candidate c/o 2023               Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig’s disease,…

eMAR

Rho Chi Talks: Tips to Acquire a Post-Doctoral Fellowship

Featuring: Kamran Khan, PharmD Candidate c/o 2023By: Justin Budz, PharmD Candidate c/o 2023 Kamran Khan is a sixth-year pharmacy student…

eMAR

Evaluating Efficacy of Bortezomib and Carfilzomib in Treatment of Refractory Multiple Myeloma

By: Brian Chung, PharmD Candidate c/o 2024, Peter Chung, PharmD Candidate c/o 2024, and Kevin Kim, PharmD Candidate c/o 2024…

eMAR

6th Year Perspective: Working with State Representatives at a Pharmacy Association

Featuring: Christina Swiger, PharmD Candidate c/o 2023By: Justin Budz, PharmD Candidate c/o 2023 Christina Swiger is a sixth-year pharmacy student…

eMAR

Evaluating the Risk of Neurodevelopmental Disorders from Antidepressant Use During Pregnancy

By: Geraldine Ciaccio, PharmD Candidate c/o 2025 ​              Pregnant women treated with antidepressants may no longer have to endure the…

eMAR

FDA Approves Tzield (teplizumab-mzwv) to Delay Onset of Type 1 Diabetes

By: Justin Budz, PharmD Candidate c/o 2023               Diabetes mellitus encompasses both chronic and reversible conditions that affect the body’s…

eMAR